Your browser doesn't support javascript.
loading
Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.
Ahmed, Farzana; Tseng, Hsin-Yi; Ahn, Antonio; Gunatilake, Dilini; Alavi, Sara; Eccles, Michael; Rizos, Helen; Gallagher, Stuart J; Tiffen, Jessamy C; Hersey, Peter; Emran, Abdullah Al.
Afiliación
  • Ahmed F; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, Australia; Melanoma Institute Australia, Sydney, Australia.
  • Tseng HY; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, Australia; Melanoma Institute Australia, Sydney, Australia; Central Clinical School, The University of Sydney, Camperdown, Australia.
  • Ahn A; Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
  • Gunatilake D; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, Australia; Melanoma Institute Australia, Sydney, Australia.
  • Alavi S; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, Australia; Melanoma Institute Australia, Sydney, Australia; Central Clinical School, The University of Sydney, Camperdown, Australia.
  • Eccles M; Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand.
  • Rizos H; Melanoma Institute Australia, Sydney, Australia; Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.
  • Gallagher SJ; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, Australia; Melanoma Institute Australia, Sydney, Australia; Central Clinical School, The University of Sydney, Camperdown, Australia.
  • Tiffen JC; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, Australia; Melanoma Institute Australia, Sydney, Australia; Central Clinical School, The University of Sydney, Camperdown, Australia.
  • Hersey P; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, Australia; Melanoma Institute Australia, Sydney, Australia; Central Clinical School, The University of Sydney, Camperdown, Australia. Electronic address: peter.hersey@sydney.edu.au.
  • Emran AA; Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, Australia; Melanoma Institute Australia, Sydney, Australia; Central Clinical School, The University of Sydney, Camperdown, Australia; Cutaneous Biology Research Center, Department of Dermatology, Massachus
J Invest Dermatol ; 142(5): 1444-1455.e10, 2022 05.
Article en En | MEDLINE | ID: mdl-34695412
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inflamasomas / Melanoma Límite: Animals / Humans Idioma: En Revista: J Invest Dermatol Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inflamasomas / Melanoma Límite: Animals / Humans Idioma: En Revista: J Invest Dermatol Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos